ERJ open research · 2026
Improving asthma control assessment and outcomes in children with asthma using an artificial intelligence digital tool: a prospective multicentre cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chang Anne B, Yerkovich Stephanie T, McPhail Steven M, Selvadurai Hiran, Goyal Vikas, George Shane, McCallum Gabrielle B, Morris Peter S, O'Farrell Hannah, Versteegh Lesley A, Grigg Jonathan, McElrea Margaret S, Worley Sophie, Elliot-Holmes Leanne, Yerkovich Terase, Williams Joanna, Grimwood Keith, Marchant Julie M
Аннотация
BACKGROUND: Achieving good asthma control is a goal of asthma management. In children, asthma control and quality-of-life assessments include determining the presence of wheeze. However, wheeze is unreliably reported with high disagreement (>50%) between parental and physician detection of wheeze. Objectively defining wheeze using WheezeScan™ (a user-friendly, artificial intelligence-based device) could improve assessment of asthma control and hence management.
OBJECTIVE: Our primary aim is to determine whether adding WheezeScan™ to routine clinical care improves parental asthma control assessment (ACA) in children (aged 4-11 years). Our secondary aims are to examine the impact of WheezeScan™ upon patient-reported outcomes (PROs), the parent asthma management self-efficacy scale (PAMS), healthcare costs and ease of WheezeScan™ use. The primary hypothesis is that using WheezeScan™ alters the ACA group.
METHODS: Our multicentre prospective cohort study involves 125 children with specialist-confirmed asthma. Over 5 weeks, parents/caregivers use the WheezeScan™ twice-daily at home and whenever wheezing is suspected. After the first week of using the WheezeScan™, asthma medications may be adjusted based upon the child's asthma control score and WheezeScan™ data. Study outcomes are collected at baseline, week 1 and week 5. Our primary end-point is the proportion of children whose assessment of asthma control changed between week 1 and baseline, based upon parental assessments using WheezeScan™ data. Secondary outcomes are PROs (asthma-related quality of life), PAMS, healthcare costs and WheezeScan™ ease of use.
CONCLUSIONS: This protocol describes our study to determine whether using digital technology to accurately identify wheeze in children with asthma improves their asthma assessment and asthma-related PROs, including PAMS and healthcare costs.
OBJECTIVE: Our primary aim is to determine whether adding WheezeScan™ to routine clinical care improves parental asthma control assessment (ACA) in children (aged 4-11 years). Our secondary aims are to examine the impact of WheezeScan™ upon patient-reported outcomes (PROs), the parent asthma management self-efficacy scale (PAMS), healthcare costs and ease of WheezeScan™ use. The primary hypothesis is that using WheezeScan™ alters the ACA group.
METHODS: Our multicentre prospective cohort study involves 125 children with specialist-confirmed asthma. Over 5 weeks, parents/caregivers use the WheezeScan™ twice-daily at home and whenever wheezing is suspected. After the first week of using the WheezeScan™, asthma medications may be adjusted based upon the child's asthma control score and WheezeScan™ data. Study outcomes are collected at baseline, week 1 and week 5. Our primary end-point is the proportion of children whose assessment of asthma control changed between week 1 and baseline, based upon parental assessments using WheezeScan™ data. Secondary outcomes are PROs (asthma-related quality of life), PAMS, healthcare costs and WheezeScan™ ease of use.
CONCLUSIONS: This protocol describes our study to determine whether using digital technology to accurately identify wheeze in children with asthma improves their asthma assessment and asthma-related PROs, including PAMS and healthcare costs.